Single and Multiple Ascending Dose Study of KN-002

Inclusion Criteria: * Male or female, 18 - 55 years old * Willing and able to give informed consent and comply with the study * Body mass index (BMI) 18 to 32 kg/m2 and weighs at least 50 kg * Women of child bearing potential must have a negative pregnancy test and use a highly efficient birth control method * Pre-bronchodilator FEV1 ≥ 70 and ≥80% for Part 1 and Part 2 participants, respectively * Pre-Bronchodilator FEV1 ≥50% predicted and ≤100% for Part 3 * Post Bronchodilator FEV1 ≥40 and ≤ 85% for Part 4 Exclusion Criteria: * Clinically significant laboratory test abnormalities * Clinically significant abnormal blood pressure and/or pulse rate * Resting ECG clinically significant abnormalities * Respiratory tract infection within 6 weeks of screening * Positive test for active COVID-19 within 2 days prior to administration of IMP